Media Articles Related to Diphenoxylate and Atropine (Diphenoxylate / Atropine)
C difficile-Associated Diarrhea in the Oncology Patient
Source: Medscape Critical Care Headlines [2017.04.20]
What is the best treatment option for C difficile in patients with cancer?
Journal of Oncology Practice
Chaining up diarrhea pathogens
Source: Biology / Biochemistry News From Medical News Today [2017.04.20]
Vaccinations are known to protect against pathogens such as bacteria or viruses.
Source: MedicineNet Addison Disease Specialty [2017.03.21]
Category: Symptoms and Signs
Created: 10/13/2003 12:00:00 AM
Last Editorial Review: 3/21/2017 12:00:00 AM
HIV and diarrhea: Causes, treatment, and remedies
Source: HIV / AIDS News From Medical News Today [2017.03.12]
What is the connection between diarrhea and HIV, when might it occur, and how long does it last? Are there any complications with HIV and diarrhea?
Xermelo Approved for Tumor-Related Diarrhea
Source: MedicineNet Electrolytes Specialty [2017.03.02]
Title: Xermelo Approved for Tumor-Related Diarrhea
Category: Health News
Created: 3/1/2017 12:00:00 AM
Last Editorial Review: 3/2/2017 12:00:00 AM
Published Studies Related to Diphenoxylate and Atropine (Diphenoxylate / Atropine)
Pretreatment with Diphenoxylate Hydrochloride/Atropine Sulfate (Lomotil) does not Decrease Physiologic Bowel FDG Activity on PET/CT Scans of the Abdomen and Pelvis. [2009.03]
CONCLUSIONS: Pretreatment with Lomotil prior to PET/CT scanning confers no benefit toward the reduction of physiologic FDG uptake by the small bowel and colon.
Are one or two dangerous? Diphenoxylate-atropine exposure in toddlers. [2008.01]
Lomotil (Pfizer Inc., New York, NY) (diphenoxylate-atropine) is said to be potentially toxic to toddlers with exposure to as little as one to two tablets. A review of the data on diphenoxylate-atropine poisonings from the American Association of Poison Control Centers annual reports, review articles, and case series disputes this view.
Diphenoxylate-atropine (Lomotil) overdose in children: an update (report of eight cases and review of the literature) [1991.05]
Eight pediatric accidental overdoses of diphenoxylate-atropine (Lomotil) are reported, and 28 literature cases are reviewed. This overdose is primarily an opioid intoxication, occasionally associated with atropine toxicity.Recommended treatment is intravenous naloxone for depressed or inadequate respirations, followed by continuous intravenous naloxone infusion, prompt gastric lavage, repeated administration of activated charcoal, and close monitoring for 24 hours.
Effect of liquid diphenoxylate hydrochloride and atropine sulfate (Lomotil) instillations on dynamics and function of continent cecal urinary reservoirs. [1987.10]
We assessed the impact of twice daily instillations of 10 ml...
Clinical Trials Related to Diphenoxylate and Atropine (Diphenoxylate / Atropine)
Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET [Completed]
2-[18F]-fluoro-2-deoxyD-glucose positron emission tomography (FDG PET) has proven to be a
valuable clinical tool for the staging and surveillance of lymphoma. 1-6 Occasionally, lymph
nodes in the mesentery and retroperitoneum can be difficult to distinguish from normal bowel
activity on PET scans despite three-plane and cine maximal image projection (MIP) imaging.
This uncertainty limits the clinical usefulness of PET in some cases of lymphoma. 7-8 In
addition, bowel activity can also hinder interpretation of PET scans in other types of solid
tumors including melanoma and colorectal cancer. 6,9,10 Our goal is to determine how well
diphenoxylate/atropine 5mg/0. 05mg (Lomotil) decreases bowel activity and how this decrease
impacts clinical decision-making, specifically for lymphoma staging and surveillance. This
is a prospective, randomized, double-blinded study involving 60 patients undergoing PET
scans for newly diagnosed or recurrent, untreated lymphoma.
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 [Withdrawn]
MP-101 will be evaluated in this study to see if it is safe and tolerable.
A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals [Withdrawn]
MP-101 will be evaluated in this study to see if it is safe, tolerable, and can help people
with Short Bowel Syndrome. This study will also find out if taking MP-101 can improve the
symptoms of Short Bowel Syndrome and reduce the number of times subjects experience bowel